Breast Cancer | Specialty

Metastatic Triple-Negative Breast Cancer Ongoing Trials

August 13th 2020

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

August 13th 2020

Metastatic HR+ Breast Cancer Updates

August 13th 2020

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

August 12th 2020

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Burris Talks Research and Regulatory Advances in TNBC

August 12th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.

Dr. Burris on Treatment Considerations in TNBC

August 11th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

Dr. Khong on the Potential Benefit of IO/Endocrine Therapy in ER+ Breast Cancer

August 11th 2020

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

August 10th 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Dr. Ahmed on the Role of Multidisciplinary Care in Breast Cancer Brain Metastases

August 10th 2020

Kamran A. Ahmed, MD, discusses the role of multidisciplinary care in breast cancer–related brain metastases.

CDK4/6 Inhibitors Make Headway in HER2+ and Triple-Negative Breast Cancers

August 10th 2020

CDK4/6 inhibitors alone and/or in combination with HER2-directed therapies have been shown to elicit encouraging response rates and inhibit the growth of the cancer cells in HER2-positive breast cancer.

Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC

August 7th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

Refining Risk-Adapted Therapy in ER+ Breast Cancer

August 7th 2020

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.

Atezolizumab/Chemotherapy Combo Misses PFS Endpoint in Frontline PD-L1+ TNBC

August 7th 2020

Atezolizumab in combination with paclitaxel did not demonstrate a statistically significant improvement in progression-free survival as a first-line treatment for patients with PD-L1–positive triple-negative breast cancer, failing to meet the primary end point of the IMpassion131 trial.

Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases

August 6th 2020

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

PI3K Inhibitors and Oral Taxanes for Metastatic Breast Cancer: Where Do They Fit In?

August 6th 2020

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

Dr. Soliman on the Rationale for Using Immunotherapy in TNBC

August 4th 2020

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

August 1st 2020

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Deciphering DNA Repair Deficiency in Breast Cancer

July 31st 2020

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Managing Systemic Toxicities and Limiting Therapy Non-Adherence in Breast Cancer

July 31st 2020

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Dr. O’Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast Cancer

July 31st 2020

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.